Karyopharm Therapeutics (KPTI) Q4 2024 earnings summary

Executive summary

• Achieved total revenue of $145.2M in 2024, with U.S. XPOVIO net product revenue at $112.8M and a profitable U.S. commercial operation.

• Advanced pivotal phase III clinical trials in myelofibrosis (SENTRY), endometrial cancer (XPORT-EC-042), and multiple myeloma, with key data readouts expected in 2025 and 2026.

• Implemented cost reduction initiatives, reducing SG&A and total expenses, and improved net loss to $76.4M from $143.1M in 2023.

• Expanded global access for selinexor with new approvals and reimbursement in over 45 countries.

• Announced modifications to phase III trial designs after FDA discussions, focusing on specific patient populations and updated endpoints.

Financial highlights

• 2024 total revenue was $145.2M, with Q4 revenue at $30.5M; U.S. XPOVIO net product revenue was $112.8M, with Q4 at $29.3M.

• R&D expenses for 2024 were $143.2M, SG&A expenses dropped to $115.4M; operating expenses totaled $264.7M.

• Net loss for 2024 was $76.4M, improved from $143.1M in 2023, aided by non-cash gains.

• Ended 2024 with $109.1M in cash, cash equivalents, and investments, down from $192.4M at end of 2023.

• Interest expense rose to $37.4M in 2024 due to new term loan and convertible debt.

Outlook and guidance

• 2025 total revenue guidance: $140–$155M; U.S. XPOVIO net product revenue projected at $115–$130M.

• R&D and SG&A expenses expected to be $240–$255M in 2025, including ~$20M in non-cash stock compensation.

• Cash runway expected to fund operations into Q1 2026, or Q4 2025 considering debt repayment and liquidity covenants.

• Exploring financing and business development activities to extend cash runway beyond 2026.

• Key 2025 milestones: preliminary Phase 2 SENTRY-2 data in 1H 2025, top-line Phase 3 SENTRY data in 2H 2025, and commercial launch readiness for myelofibrosis.